Effects of acute and long-term typical or atypical neuroleptics on morphine-induced behavioural effects in mice

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 3, 2014, Pages 255-263

  Hollais, André W ^a   Patti, Camilla L ^a   Zanin, Karina A ^a   Fukushiro, Daniela F ^a   Berro, Laís F ^a   Carvalho, Rita C ^a   Kameda, Sonia R ^a   Frussa Filho, Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dopamine; Haloperidol; Hyperactivity; Mor phine; Open field; Ziprasidone

Indexed keywords

HALOPERIDOL; MORPHINE; MORPHINE SULFATE; ZIPRASIDONE;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GROOMING; IMMOBILITY; LOCOMOTION; LONG TERM CARE; MOTOR ACTIVITY; MOUSE; NONHUMAN; OPEN FIELD TEST; REARING; SCHIZOPHRENIA; TREATMENT DURATION;

DOPAMINE; HALOPERIDOL; HYPERACTIVITY; MOR-PHINE; OPEN-FIELD; ZIPRASIDONE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; FEMALE; HALOPERIDOL; MICE; MORPHINE; MOTOR ACTIVITY; PIPERAZINES; SUBSTANCE WITHDRAWAL SYNDROME; THIAZOLES;

EID: 84896321380     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12203     Document Type: Article

References (42)

1. Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990; 264: 2511-8.
2. Westermeyer J. Comorbid schizophrenia and substance abuse. A review of epidemiology and course. Am. J. Addict. 2006; 15: 345-55.
3. Green AI. Schizophrenia and comorbid substance use disorder: Effects of antipsychotics. J. Clin. Psychiatry 2005; 66: 21-26.
4. LeDuc PA, Mittleman G. Schizophrenia and psychostimulant abuse. A review and re-analysis of clinical evidence. Psychopharmacology 1995; 121: 407-27 [Review].
5. Vital MA, Flório JC, Frussa-Filho R, De Lucia R, Tufik S, Palermo-Neto J. Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover. Life Sci. 1998; 62: 1161-9.
6. Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL. Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: Differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology 1997; 17: 186-96.
7. Prosser ES, Csernansky JG, Hollister LE. Differences in the time course of haloperidol-induced up-regulation of rat striatal and mesolimbic dopamine receptors. Life Sci. 1988; 43: 715-20.
8. Prosser ES, Pruthi R, Csernansky JG. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology 1989; 99: 109-16.
9. Frussa-Filho R, Palermo-Neto J. Effects of single and long-term droperidol administration on open-field and stereotyped behavior of rats. Physiol. Behav. 1991; 50: 825-30.
10. Frussa-Filho R, Palermo-Neto J. Effects of single and long-term administration of sulpiride on open-field and stereotyped behavior of rats. Braz. J. Med. Biol. Res. 1990; 23: 463-72.
11. Frussa-Filho R, Palermo-Neto J. Effects of single and long-term metoclopramide administration on open field and stereotyped behavior of rats. Eur. J. Pharmacol. 1988; 149: 323-9.
12. Felicio LF, Nasello AG, Palermo-Neto J. Dopaminergic supersensitivity after long-term bromopride treatment. Physiol. Behav. 1987; 41: 433-7.
13. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA 1988; 85: 5274-8.
14. Fukushiro DF, Carvalho RC, Ricardo VP, Alvarez JdoN, Ribeiro LTC, Frussa-Filho R. Haloperidol (but not ziprazidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice. Brain Res. Bul. 2008; 77: 124-8.
15. Fukushiro DF, Alvarez Jdo N, Tatsu JA, de Castro JP, Chinen CC, Frussa-Filho R. Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 867-72.
16. 2 receptors. Addict. Biol. 2009; 14: 283-93.
17. Al-Khatib IM, Dökmeci I, Fujiwara M. Differential role of nucleus accumbens and caudate-putamen in mediating the effect of nomifensine and methamphetamine on ambulation and rearing of rats in the open-field test. Jpn. J. Pharmacol. 1995; 67: 69-77.
18. Delfs JM, Schreiber L, Kelley AE. Microinjection of cocaine into the nucleus accumbens elicits locomotor activation in the rat. J. Neurosci. 1990; 10: 303-10.
19. Kelly PH, Seviour PW, Iversen SD. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 1975; 94: 507-22.
20. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 2001; 425: 197-201.
21. Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57-73.
22. 2 antagonists modulate the effects of D-2 dopamine receptor blockade. J. Pharmacol. Exp. Ther. 1990; 253: 1162-70.
23. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 1989; 251: 238-46.
24. Chinen CC, Faria RR, Frussa-Filho R. Characterization of the rapid-onset type of behavioral sensitization to amphetamine in mice: Role of drug-environment conditioning. Neuropsychopharmacology 2006; 31: 151-9.
25. Bernardi MM, Scavone C, Frussa-Filho R. Differential effects of single and long-term amphetamine and apomorphine administrations on locomotor activity of rats. Gen. Pharmacol. 1986; 17: 465-8.
26. Patti CL, Frussa-Filho R, Silva RH et al. Behavioral characterization of morphine effects on motor activity in mice. Pharmacol. Biochem. Behav. 2005; 81: 923-7.
27. Stevens KE, Mickley GA, McDermott LJ. Brain areas involved in production of morphine-induced locomotor hyperactivity of the C57B1/6J mouse. Pharmacol. Biochem. Behav. 1986; 24: 1739-47.
28. Vaccarino FJ, Amalric M, Swerdlow NR, Koob GF. Blockade of amphetamine but not opiate-induced locomotion following antagonism of dopamine function in the rat. Pharmacol. Biochem. Behav. 1986; 24: 61-65.
29. Murphy NP, Lam HA, Maidment NT. A comparison of morphine-induced locomotor activity and mesolimbic dopamine release in C57BL6, 129Sv and DBA2 mice. J. Neurochem. 2001; 79: 626-35.
30. Kalivas PW, Widerlöv E, Stanley D, Breese G, Prange AJ Jr. Enkephalin action on the mesolimbic system: A dopamine-dependent and a dopamine-independent increase in locomotor activity. J. Pharmacol. Exp. Ther. 1983; 227: 229-37.
31. Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science 1977; 196: 326-8.
32. Palermo-Neto J, Frussa-Filho R, Vital MA. Kinetic analysis of GM1 effects on haloperidol-induced dopaminergic supersensitivity. Gen. Pharmacol. 1999; 32: 265-70.
33. Palermo-Neto J, Bernardi MM. Kinetic analysis of central nervous system supersensitivity induced in rats by long-term haloperidol administration. Part II. KB determination. Psychopharmacol. Bull. 1984; 20: 681-3.
34. Perry JC, Vital MA, Frussa-Filho R, Tufik S, Palermo-Neto J. Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats. Eur. Neuropsychopharmacol. 2004; 14: 127-33.
35. Abílio VC, Freitas FM, Dolnikoff MS, Castrucci AM, Frussa-Filho R. Effects of continuous exposure to light on behavioral dopaminergic supersensitivity. Biol. Psychiatry 1999; 45: 1622-9.
36. Abílio VC, Vera JA Jr, Ferreira LC et al. Effects of melatonin on behavioral dopaminergic supersensitivity. Life Sci. 2003; 72: 3003-15.
37. Vital MA, Frussa-Filho R, Palermo-Neto J. Effects of monosialoganglioside on dopaminergic supersensitivity. Life Sci. 1995; 56: 2299-307.
38. Torigoe K, Mori T, Shibasaki M, Yoshizawa K, Narita M, Suzuki T. Olanzapine suppresses the rewarding and discriminative stimulus effects induced by morphine. Synapse 2012; 66: 174-9.
39. White FJ, Hu XT, Brooderson RJ. Repeated stimulation of dopamine D1 receptors enhances the effects of dopamine receptor agonists. Eur. J. Pharmacol. 1990; 191: 497-9.
40. Braun AR, Chase TN. Obligatory D1/D2 receptor interaction in the generation of dopamine agonist related behaviors. Eur. J. Pharmacol. 1986; 131: 301-6.
41. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin. Ther. Targets 2006; 10: 515-31.
42. Holtman JR Jr, Sloan JW, Wala EP. Morphine tolerance in male and female rats. Pharmacol. Biochem. Behav. 2004; 77: 517-23.